China Gewang Biotechnology (CGWB) 10-K 10 Feb 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Nov. 30, 2016	Feb. 10, 2017	May 31, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA GEWANG BIOTECHNOLOGY, INC.
Entity Central Index Key	1,489,902
Amendment Flag	false
Current Fiscal Year End Date	--11-30
Document Type	10-K
Document Period End Date	Nov. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 129,148,425
Entity Common Stock, Shares Outstanding		75,000,000

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Nov. 30, 2016	Nov. 30, 2015
Current assets:
Cash	$ 13,108,340	$ 8,669,034
Accounts receivable	11,205,011	267,868
Inventory	107,830	156,778
Prepaid expenses	5,540,051	201,369
Total current assets	29,961,232	9,295,049
Property, plant and equipment, net	128,767	65,860
Other assets:
Deferred registration cost	110,086
Equity Method Investments	6,003,412
TOTAL ASSETS	36,203,497	9,360,909
Current liabilities:
Accounts payable	3,367,174
Taxes payable	789,370	64,153
Accrued expenses and other payables	193,090	175,086
Loans from third party	228,238
Loans from stockholder	237,639
Total current liabilities	4,815,511	405,345
Commitments and contingencies
Stockholders' equity:
Common stock - $0.001 par value, 100,000,000 and 75,000,000 shares authorized, 75,000,000 and 45,500,000 shares issued and outstanding as of November 30, 2016 and November 30, 2015, respectively	75,000	45,500
Additional paid-in capital	16,980,102	6,525,743
Retained earnings	15,026,053	2,270,416
Statutory reserve fund	759,094	281,766
Other comprehensive (loss)	(1,707,064)	(252,022)
Stockholders' equity before noncontrolling interests	31,133,185	8,871,403
Noncontrolling interests	254,801	84,161
Total stockholders' equity	31,387,986	8,955,564
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 36,203,497	$ 9,360,909

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Nov. 30, 2016	Nov. 30, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	75,000,000
Common stock, shares issued	75,000,000	45,500,000
Common stock, shares outstanding	75,000,000	45,500,000

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Income Statement [Abstract]
Net revenues	$ 45,519,999	$ 4,184,255	$ 45,519,999
Cost of goods sold	(28,765,888)	(1,186,461)	(725,449)
Gross profit	16,754,111	2,997,794	1,642,567
Operating expenses:
Selling and marketing	3,044,135	836,040	473,670
General and administrative	1,005,385	528,627	150,154
Research and development	605,816
Total operating expenses	4,655,336	1,364,667	623,824
Operating income	12,098,775	1,633,127	1,018,743
Other income
Interest income	14,868	13,508	2,900
Income before provision for income taxes	12,113,643	1,646,635	1,021,643
Provision for income taxes	3,075,733	457,922	264,553
Equity in income of investee	4,536,760
Net income before noncontrolling interests	13,574,670	1,188,713	757,090
Noncontrolling interests	(326,213)	(61,790)	(38,952)
Net income attributable to common stockholders	$ 13,248,457	$ 1,126,923	$ 718,138
Earnings per common share	$ 0.20	$ 0.03	$ 0.02
Weighted average shares outstanding	65,441,257	40,944,444	35,500,000
Comprehensive income
Net income before noncontrolling interests	$ 13,574,670	$ 1,188,713	$ 757,090
Foreign currency translation adjustment	(1,455,633)	(315,020)	1,333
Total comprehensive income	12,119,037	873,693	758,423
Comprehensive (loss) income attributable to noncontrolling interests	(170,640)	(46,039)	(39,019)
Net comprehensive income attributable to common stockholders	$ 11,948,397	$ 827,654	$ 719,404

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Noncon- trolling Interests	Statutory Reserve Fund	Other Comprehensive Income (Loss)
Balance, beginning at Nov. 30, 2013	$ 2,309,666	$ 35,500	$ 1,539,275	$ 592,024	$ 16,113	$ 65,089	$ 61,665
Net income	784,152			761,313	22,839
Statutory reserve				(76,131)		76,131
Other comprehensive income (loss)	1,333			67			1,226
Balance, ending at Nov. 30, 2014	3,098,452	35,500	1,539,275	1,277,273	38,952	144,454	62,998
Reverse merger adjustment			(3,532)	3,532
Issuance of common stock	5,000,000	10,000	4,990,000
Net income	1,188,713			1,126,923	61,790
Statutory reserve				(137,312)		137,312
Other comprehensive income (loss)	(331,601)				(16,581)		(315,020)
Balance, ending at Nov. 30, 2015	8,955,564	45,500	6,525,743	2,270,416	84,161	281,766	(252,022)
Issuance of common stock	9,848,200	29,500	9,818,700
Equity in excess of purchase price of investee under common control	466,652		466,652
Acquisition of VIE non-controlling interest	(1,467)		169,007	135,147	(264,372)	(15,492)	(25,757)
Net income	13,574,670			13,113,310	461,360
Statutory reserve				(492,820)		492,820
Other comprehensive income (loss)	(1,455,633)				(26,348)		(1,429,285)
Balance, ending at Nov. 30, 2016	$ 31,387,986	$ 75,000	$ 16,980,102	$ 15,026,053	$ 254,801	$ 759,094	$ (1,707,064)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Cash flows from operating activities:
Net income	$ 13,574,670	$ 1,188,713	$ 784,152
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	52,919	32,121	25,962
(Income) from equity investment	(4,536,760)
Changes in operating assets and liabilities:
(Increase) in accounts receivable	(10,937,143)	(267,868)
Decrease (increase) in inventory	48,948	(102,782)	(53,996)
(Increase) in prepaid expenses	(5,338,682)	(96,169)	(90,470)
Increase (decrease) in accounts payable	3,367,174	(7,225)
(Decrease) in advances from customers		(56,930)	(14,997)
Increase in taxes payable	725,217	16,824	29,345
Increase in accrued expenses and other payables	207,689	330,936	9,410
Net cash (used in) provided by operating activities	(2,835,968)	1,037,620	728,904
Cash flows from investing activities:
Purchase of equipment	(123,352)	(52,485)	(6,676)
Payment for equity in investee	(995,811)
Net cash (used in) investing activities	(1,119,163)	(52,485)	(6,676)
Cash flows from financing activities:
Proceeds from sale of common stock	9,848,200	5,000,000
Net cash provided by financing activities	9,848,200	5,000,000
Effect of exchange rate changes on cash	(1,453,763)	(328,913)	1,366
Net change in cash	4,439,306	5,656,222	723,594
Cash, beginning	8,669,034	3,012,812	2,289,218
Cash, end	13,108,340	8,669,034	3,012,812
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes	2,543,744	446,012	238,026
Additional paid-in capital - equity in excess of purchase price of investee under common control	466,652
Noncash financing activities:
Payment of accrued expenses and other payables by shareholder	$ 298,938	$ 159,689	$ 6,417

Organization

Organization	12 Months Ended
	Nov. 30, 2016
Organization [Abstract]
ORGANIZATION	1. ORGANIZATION China Gewang Biotechnology, Inc. (the “Company”), formerly known as Rich Star Development, was incorporated under the laws of the State of Nevada on May 29, 2009. From its inception until the closing of the reverse merger described below, the Company was a development-stage company in the business of sourcing and distributing food products, paper products, janitorial products, restaurant utensils and equipment to the food service industry in the PRC. On April 20, 2015, the Company completed a reverse merger transaction through a share exchange with the stockholders of Biotechnology International Holding Ltd. (“Biotechnology International”), whereby the Company acquired 100% of the outstanding shares of Biotechnology International in exchange for 32,000,000 shares of its common stock, representing 90.14% of the issued and outstanding shares of common stock. As a result of the reverse merger, Biotechnology International became the Company’s wholly-owned subsidiary and the former Biotechnology International stockholders became our controlling stockholders. The share exchange transaction was treated as a reverse acquisition, with Biotechnology International as the acquirer and the Company as the acquired party for accounting purposes. On January 8, 2015, the Company filed a certificate of amendment to its articles of incorporation to change its name from “Rich Star Development” to “China Gewang Biotechnology, Inc.” On July 20, 2016 the Company filed with the Nevada Secretary of State a Certificate of Amendment to Articles of Incorporation. The Certificate of Amendment increased the number of authorized shares of common stock from 75 million to 100 million. Majority-owned subsidiary: Gu angdong Gewang As a result of the transaction with Biotechnology International, the Company owns all of the issued and outstanding common stock of Hong Kong Gewang Holdings Group Limited (“Hong Kong Gewang”), a wholly-owned subsidiary of Biotechnology International, which in turn owns all of the issued and outstanding common stock of Gewang Selenium Enrichment Information Consulting (Shenzhen) Co., Ltd. (“Gewang Selenium”). Before August 8, 2016, the Company effectively and substantially controlled Guangdong Gewang Biotechnology Co., Ltd. (“Guangdong Gewang”) through a series of captive agreements between Guangdong Gewang and Gewang Selenium. Guangdong Gewang, incorporated under the laws of the People’s Republic of China (“PRC”) on June 2010, is primarily engaged in the sale of selenium supplements within the PRC. It is a member of the Chinese Selenium Supplements Association. On July 13, 2016, Gewang Selenium exercised its option to purchase all of the registered equity of Guangdong Gewang. The purchase price paid for the equity was RMB10,000 (approximately $1,500). The equity was purchased from Shili Zhang, Yun Zeng and Wei Xu. Shili Zhang was the Company’s CEO until April 8, 2016 and is the father of Mengdi Zhang, who was the beneficial owner of 22.7% of the Company's outstanding common stock at the time of the sale on July 13, 2016. The other two sellers are not affiliated with the Company. Upon application to the provincial government for registration of the transfer of equity, the Company was informed that Gewang Selenium would not be permitted to own 100% of Guangdong Gewang. Therefore the parties modified the exercise of the option to provide that Gewang Selenium would purchase only 98% of the registered equity of Guangdong Gewang. The purchase price paid for the equity was RMB 9,800 (approximately $1,500). The remaining 2% of the registered equity was then sold by Yun Zeng to Haiping Wu for a price of RMB 200,000 (approximately $30,400), which equaled 2% of the registered equity of Guangdong Gewang. Haiping Wu is a Director of Guangdong Gewang. The acquisition, as modified, was then approved by the provincial government on August 8, 2016. Prior to the acquisition, Gewang Selenium controlled Guangdong Gewang through a series of contractual agreements, which made Guangdong Gewang a variable interest entity, the effect of which was to cause the balance sheet and operating results of Guangdong Gewang to be consolidated with those of Gewang Selenium in the Company's financial statements. As a result of the acquisition by Gewang Selenium of registered ownership of Guangdong Gewang, the balance sheet and operating results of Guangdong Gewang will hereafter continue to be consolidated with those of Gewang Selenium as its majority-owned subsidiary. The previous non-controlling interest was reclassified to additional paid-in-capital. Equity investment: Guangdong Tianmei On April 28, 2016, the Company's wholly-owned subsidiary, Biotechnology International, entered into an investment agreement with Guangdong Tianmei Selenium-Rich Beverage Chain Co., Ltd. (“Guangdong Tianmei”). Guangdong Tianmei was organized in May 2015, and is engaged in the business of distributing selenium-rich bottled water and also functions as a placement agent for a variety of products from various manufacturers, all within the PRC. The investment agreement provided that Biotechnology International would pay US$1,000,000 to acquire a 30% interest in an Australian corporation to be formed, which would indirectly own all of the equity in Guangdong Tianmei. The foregoing acquisition by Biotechnology International of 30% of Tianmei Beverage Group Corporation Limited, an Australian corporation ("Tianmei Australia"), was completed in May 2016, at which time Tianmei Australia acquired ownership, through subsidiaries, of Guangdong Tianmei. The $1,000,000 purchase price was paid in full on June 17, 2016. As a result of the entry into the foregoing agreements, the Company has a corporate structure which is as follows:

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Nov. 30, 2016
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of accounting and presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include those of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting for its equity investments in Tianmei Australia. The investment was under common control and can be significantly influenced. Under the equity method, investments are carried at cost and increased or decreased by the Company’s pro-rata share of earnings or losses. The carrying costs of these investments is also increased or decreased to reflect additional contributions or withdrawals of capital. Any difference in the book equity and the Company’s pro-rata share of the net assets of the investment will be reported as gain or loss at the liquidation of the investment. Losses in excess of the investments are recorded when the Company is committed to provide additional financial support. The Company uses the equity method for investment of 30% because the Company has the ability to exercise significant influence over these entities. All consolidated financial statements and notes to the consolidated financial statements are presented in United States dollars (“US Dollar” or “US$” or “$”). Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Foreign currency translations Almost all of the Company assets are located in the PRC. The functional currency for the Company’s operations is the Renminbi (“RMB”). The Company uses the United States Dollar (“US Dollar” or “US$” or “$”) for financial reporting purposes. The financial statements of the Company have been translated into US Dollars in accordance with Financial Accounting Standards Board ("FASB”) Accounting Standards Update ("ASU") Section 830, “ Foreign Currency Matters All asset and liability accounts have been translated using the exchange rate in effect at the balance sheet date. Equity accounts have been translated at their historical exchange rates when the capital transactions occurred. Statements of income (loss) and comprehensive income (loss), changes in stockholders’ equity and cash flows have been translated using the average exchange rate for the periods presented. Adjustments resulting from the translation of the Company’s financial statements are recorded as other comprehensive income (loss). The exchange rates used to translate amounts in RMB into US Dollars for the purposes of preparing the financial statements are as follows: November 30, 2016 November 30, 2015 November 30, 2014 Balance sheet items, except for stockholders’ equity, as of year end 0.1452 0.1561 0.1631 Year Ended November 30, 2016 2015 2014 Amounts included in the statements of income and comprehensive income, changes in stockholders’ equity and cash flows for the year presented 0.1515 0.1610 0.1628 For the years ended November 30, 2016, 2015 and 2014, foreign currency translation adjustments of $(1,455,633), $(315,020), and $1,333, respectively, have been reported as other comprehensive income (loss). Other comprehensive income (loss) of the Company consists entirely of foreign currency translation adjustments. Although PRC government regulations now allow convertibility of the RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that the RMB could be converted into US Dollars at that rate or any other rate. The value of the RMB against the US Dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC’s political and economic conditions. Any significant revaluation of the RMB may materially affect the Company’s financial condition in terms of US Dollar reporting. In August 2015, the PRC devalued its currency by approximately 3.5%; in January 2016 the PRC devalued its currency by an additional 0.5%; from February 2016 to November 2016, the PRC devalued its currency by an additional 7%. Further devaluations of its currency could occur. Revenue recognition Revenues are primarily derived from selling selenium supplements and selenium products to wholesale customers, contract distributors, and from our retail stores. The Company’s revenue recognition policies comply with FASB ASC 605 “ Revenue Recognition. Wholesale Revenue Wholesale revenue is recognized when title to the product is transferred to the distributors. Title is transferred upon receipt at the distributors’ locations, as determined by the specific sales terms. The Company pays distributors certain incentives for promoting and placing its products, which allows the Company to quickly expand its distribution network and sales volume. The costs associated with these incentives is deducted from gross revenue in the consolidated statements of income and comprehensive income Retail Revenue Company-operated retail store revenues are recognized when payment is tendered at the point of sale. Franchise Revenue In June 2016, the Company commenced franchising the use of the Company's trademark, name identification and other business resources. The franchisee is required to pay franchise fees and management fees to the Company. Franchise fees are recognized only when all material services or conditions relating to the sale have been substantially performed or satisfied by the Company. In September 2016, the Company terminated its two franchise agreements for marketing reasons. The Company returned the total franchise fees to the franchisees and kept the management fees of $35,290 as per the termination agreements. The Company’s net revenues for the years ended November 30, 2016, 2015 and 2014 were comprised as follows: 2016 2015 2014 Wholesale gross revenue-selenium supplements $ 8,600,092 $ 2,945,440 $ 1,930,057 Wholesale gross revenue-selenium products 36,306,396 - - Less: promotion fees-selenium products, (3,745,883 ) - - Wholesale revenues, net 41,160,605 2,945,440 1,930,057 Retail revenue-selenium supplements 2,946,182 - - Retail revenues-selenium products 1,377,922 1,238,815 437,959 Management fee revenues 35,290 - - $ 45,519,999 $ 4,184,255 $ 2,368,016 Shipping costs Shipping costs incurred by the Company are recorded as selling expenses. Shipping costs for the years ended November 30, 2016, 2015 and 2014 were $96,969, $44,326 and $27,545, respectively. Advertising costs Advertising costs are charged to operations when incurred. For the years ended November 30, 2016, 2015 and 2014, advertising expenses were $619,447, $82,110 and $70,013, respectively. Cash and cash equivalents The Company considers all demand and time deposits and all highly liquid investments with an original maturity of three months or less to be cash equivalents. Accounts receivable Accounts receivable are recorded at the contract amount after deduction of trade discounts and, allowances, if any, and do not bear interest. The allowance for doubtful accounts, when necessary, is the Company’s best estimate of the amount of probable credit losses from accounts receivable. The Company determines the allowance based on historical write-off experience, the level of past-due accounts based on the contractual terms of the receivable, the relationship with the customer and current economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. As of November 30, 2016, 2015 and 2014, accounts receivable were $11,205,011, $267,868 and $0, respectively. The increase is primarily due to the recent sales with new wholesale distributors which has been subsequently fully collected. Therefore, the Company determined that an allowance for doubtful accounts was not necessary. Historically, the Company did not have any uncollectable accounts receivable. Inventory Inventory, comprised principally of boxed selenium capsules, selenium-glossy ganoderma capsules and selenium powder, is valued at the lower of cost or market. The value of inventory is determined using the first-in, first-out method. The Company periodically estimates an inventory allowance for estimated unmarketable inventories when necessary. Inventory amounts are reported net of such allowances, if any. There were no allowances for inventory as of November 30, 2016, 2015 and 2014. Fair value of financial instruments FASB ASC 820, “Fair Value Measurement” Level 1 Inputs – Unadjusted quoted market prices for identical assets and liabilities in an active market that the Company has the ability to access. Level 2 Inputs – Inputs other than the quoted prices in active markets that are observable either directly or indirectly. Level 3 Inputs – Inputs based on valuation techniques that are both unobservable and significant to the overall fair value measurements. ASC 820 requires the use of observable market data, when available, in making fair value measurements. When inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value of financial instruments (continued) The Company did not identify any assets or liabilities that are required to be presented at fair value on a recurring basis. Carrying values of non-derivative financial instruments, including cash and cash equivalents, accounts receivable, inventory, prepaid expenses, equity investment, accounts payable, taxes payable, accrued liabilities and other payables, and loan from stockholder, approximated their fair values due to the short nature of these financial instruments. There were no changes in methods or assumptions during the periods presented. Prepaid expenses Prepaid expenses primarily consist of promotion expenses, rent, advertising expenses and licensing fees. Prepaid promotion expenses represent prepayments made to resellers for distributing products to retail stores. In March 2016, the Company entered into agreements with four distributors. In June, July and September 2016, the Company entered into agreements with another four distributors. Prepaid promotion expenses as of November 30, 2016, 2015 and 2014 were $4,275,602, $0 and $0, respectively. On January 5, 2011, the Company entered into a license agreement for the technology utilized for the manufacture of its products from an unrelated third party for five years from January 2011 to December 2015. On December 30, 2015, the Company renewed the license agreement for another five years to December 2020 for $90,872 (RMB 600,000) each year. The related prepaid licensing fees as of November 30, 2016, 2015 and 2014 were $7,259, $7,805 and $8,155, respectively. The license provides for renewal options. Since this agreement requires the advance payment of the annual licensing fee, there were no minimum payments remaining under this agreement as of November 30, 2016, 2015 and 2014. On September 30, 2016, the Company entered into a six-month agreement with an advertising company for $908,725 (RMB 6,000,000). As of November 30, 2016, the unamortized balance of $605,816 was included in prepaid expenses on the balance sheet. The Company applies FASB ASC 360, “ Property, Plant and Equipment Statutory reserve fund Pursuant to corporate law of the PRC, the Company is required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory reserve fund until such reserve balance reaches 50% of the Company’s registered capital. The statutory reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or used to increase registered capital, provided that the remaining reserve balance after use is not less than 25% of registered capital. The statutory reserve fund was $759,094, $281,766, and $144,454 as of November 30, 2016, 2015 and 2014, respectively. As of November 30, 2016, the required statutory reserve fund has been fully funded. Income taxes The Company accounts for income taxes in accordance with FASB ASC 740, “ Income Taxes Income taxes (continued) ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions. As of November 30, 2016, 2015 and 2014, the Company does not have a liability for any unrecognized tax benefits. The Company’s tax filings are subject to examination by the tax authorities. The tax years of 2103, 2014 and 2015 remain open to examination by tax authorities in the PRC. The income tax laws of various jurisdictions in which the Company and its subsidiaries operate are summarized as follows: United States The Company is subject to United States tax at graduated rates from 15% to 35%. No provisions for income tax in the United States have been made as the Company had no U.S. taxable income for the years ended November 30, 2016, 2015 and 2014. British Virgin Islands BVI”) Biotechnology International is incorporated in the BVI and is governed by the income tax laws of the BVI. According to current BVI income tax law, the applicable income tax rate for the Company is 0%. Hong Kong Hong Kong Gewang is incorporated in Hong Kong. Pursuant to the income tax laws of Hong Kong, the Company is not subject to tax on non-Hong Kong source income. The People's Republic of China (“PRC”) Gewang Selenium and Guangdong Gewang are subject to an Enterprise Income Tax at 25% and file their own tax returns.

Recently Issued Accounting Stan

Recently Issued Accounting Standards	12 Months Ended
	Nov. 30, 2016
Recently Issued Accounting Standards [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	3. RECENTLY ISSUED ACCOUNTING STANDARDS In May 2016, the FASB issued ASU 2016-12 (Subtopic 606), “ Revenue from Contracts with Customers. In February 2016, the FASB issued ASU 2016-02, “ Leases In July 2015, the FASB issued ASU 2015-11 (Subtopic 330), “ Simplifying the Measurement of Inventory In January 2015, the FASB issued ASU 2015-01 (Subtopic 225-20), “ Income Statement – Extraordinary and Unusual Items In August 2014, the FASB issued authoritative guidance that requires an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern and requires additional disclosures if certain criteria are met. This guidance is effective for fiscal periods ending after December 15, 2016, with early adoption permitted. This accounting standard update is not expected to have a material impact on the Company’s consolidated financial statements.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Nov. 30, 2016
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	4. RELATED PARTY TRANSACTIONS The Company entered into a promotion agreement with Guangdong Tianmei, in which it holds an indirect 30% ownership interest. Promotions expenses incurred during the year ended November 30, 2016, 2015 and 2014 in connection with this relationship were $626,147, $0, and $0, respectively. The Company entered into an agreement with Guangdong Tianmei on June 10, 2015 to license the use of the Company’s trademark for 10 years. Trademark revenue recorded for the years ended November 30, 2016, 2015 and 2014 were $1,470, $0 and $0, respectively. The future commitment is approximately $1,500 each year. Equity investment On April 28, 2016, the Company's wholly-owned subsidiary, Biotechnology International, entered into an investment agreement with Guangdong Tianmei. At that time, 88% of the equity in Guangdong Tianmei was owned by two individuals who together directly or indirectly owned over 60% of the Company's outstanding shares. The investment agreement provided that Biotechnology International would pay US$1,000,000 to acquire a 30% interest in an Australian corporation to be formed, which would indirectly own all of the equity in Guangdong Tianmei. The acquisition by Biotechnology International of 30% of Tianmei Australia was completed in May 2016, at which time Tianmei Australia acquired ownership, through subsidiaries, of Guangdong Tianmei. The investment agreement provided that payment of the $1,000,000 purchase price was due on June 20, 2016, which was paid in full on June 17, 2016. The net worth of Guangdong Tianmei at the time of the acquisition was $4,888,840, 30% of which was $1,466,652. Because the Company and Guangdong Tianmei were under common control at the time of the acquisition, the $466,652 by which the Company's share of the net book value of Guangdong Tianmei exceeded the purchase price has been recorded as an increase to additional paid-in capital. The changes in the equity investment are summarized as follows: November 30, 2016 November 30, 2015 November 30, 2014 Initial investment $ 1,466,652 $ - $ - Pro rata share of net income 4,536,760 - - Investment, end of year $ 6,003,412 $ - $ - The following is a summary of balance sheet of the investee for the year ended November 30, 2016: Current assets $ 41,948,599 Noncurrent assets $ 1,321,713 Current liabilities $ 14,760,307 Noncurrent liabilities $ - Equity $ 28,510,005 The following is a summary of results of operations of the investee for the period from the acquisition date to November 30, 2016: Revenue $ 41,285,348 Cost of revenue (15,168,370 ) Expenses (10,994,445 ) Net income $ 15,122,533

Leases

Leases	12 Months Ended
	Nov. 30, 2016
Leases [Abstract]
LEASES	5. LEASES The Company leased its warehouse and office space from an unrelated third party under a one-year operating lease, which expired on July 1, 2016. The lease required the Company to prepay the total rent of $90,872 (RMB 600,000) in advance for one year. On June 29, 2016, the Company renewed the lease, which commenced on July 2, 2016 and expires on July 1, 2017. The following leases terminated during the year: ● The Company leased its Chancheng store from an unrelated third party. The lease, which expired on August 31, 2015, required the Company to prepay the rent of $41,801 (RMB 276,000) in advance for one year. The Company renewed this lease to August 31, 2016 and prepaid the rent of $54,523 (RMB 360,000) in advance for one year. On May 31, 2016, the Company terminated the lease with a $4,576 settlement fee. ● The Company leased its Xiamen store from an unrelated third party. The lease expired on June 1, 2016 and the Company decided not to renew the lease. ● The Company also leased its Changsha store from an unrelated third party. The lease, which was to expire on October 7, 2018, required the Company to prepay the rent of $63,611 (RMB 420,000) in advance for one year. On May 31, 2016, the Company terminated the lease without any settlement fee. The following leases remained in effect at November 30, 2016: ● The Company leases its flagship store in Guangzhou from an unrelated third party. The lease commenced on June 1, 2016 and expires on May 31, 2017. The lease required the Company to prepay the rent of $145,396 (RMB 960,000) in advance for one year. The Company paid the rent in June 2016. ● The Company leases its Foshan store, Longyan store and Zhuzhou store from three unrelated third parties. All three leases commenced on June 1, 2016 and expire on May 31, 2017. These leases each required the Company to prepay the rent of $63,611 (RMB 420,000) in advance for one year. The Company fully paid the rent in June 2016. Since these leases require the advance payment of the annual rent, there are no minimum payments remaining under these leases. Prepaid lease payments were $221,123 and $179,515 at November 30, 2016 and 2015, respectively. Rent expense for the years ended November 30, 2016, 2015 and 2014 was $345,315, $181,125 and $44,501, respectively.

Fixed Assets

Fixed Assets	12 Months Ended
	Nov. 30, 2016
Fixed Assets [Abstract]
FIXED ASSETS	6. FIXED ASSETS Fixed assets as of November 30, 2016 and 2015 are summarized as follows: 2016 2015 Electronic equipment $ 125,850 $ 68,733 Motor vehicles 121,151 69,714 Office equipment 12,031 12,936 259,032 151,383 Less: accumulated depreciation (130,265 ) (85,523 ) Fixed assets - net $ 128,767 $ 65,860 For the years ended November 30, 2016, 2015 and 2014, depreciation expense was $52,919 $32,121 and $25,962, respectively.

Loans

Loans	12 Months Ended
	Nov. 30, 2016
Loans [Abstract]
LOANS	7. LOANS The Company obtained demand and non-interest bearing loans from a former officer and stockholder, who resigned from office on April 8, 2016. The loans of $228,238 and $0 at November 30, 2016 and 2015, respectively, are reflected as loans from third party. The Company obtained demand and non-interest bearing loans from one of its stockholders. The loans of $237,639 and $166,106 at November 30, 2016 and 2015, respectively, are reflected as loans from stockholder.

Income Taxes

Income Taxes	12 Months Ended
	Nov. 30, 2016
Income Taxes [Abstract]
INCOME TAXES	8. INCOME TAXES The provision for income taxes for the years ended November 30, 2016, 2015 and 2014 consisted of the following: 2016 2015 2014 Current $ 3,075,733 $ 457,922 $ 264,553 Deferred - - - $ 3,075,733 $ 457,922 $ 264,553 No provisions for income taxes in the United States have been made. The Company did not generate any income in the United States or otherwise have any U.S. taxable income. The Company does not believe that it has any U.S. Federal income tax liabilities with respect to any transactions that the Company or any of its subsidiaries may have engaged in through November 30, 2016. However, there can be no assurance that the Internal Revenue Service (“IRS”) will agree with this position, and therefore the Company ultimately could be liable for U.S. Federal income taxes, interest and penalties. The tax years ended November 30, 2015, December 31, 2014, 2013 and 2012 remain open to examination by the IRS. The Company did not file on time its U.S. federal income tax returns, including, without limitation, information returns on IRS Form 5471, “ Information Return of U.S. Persons with Respect to Certain Foreign Corporations

Concentration of Credit and Bus

Concentration of Credit and Business Risks	12 Months Ended
	Nov. 30, 2016
Concentration of Credit and Business Risks [Abstract]
CONCENTRATION OF CREDIT AND BUSINESS RISKS	9. CONCENTRATION OF CREDIT AND BUSINESS RISKS Cash and cash equivalents Substantially all of the Company’s assets and bank accounts are in banks located in the PRC and are not covered by protection similar to that provided by the FDIC on funds held in United States banks. Major customers For the year ended November 30, 2016, three customers accounted for 48% of total sales. For the year ended November 30, 2015, no customers accounted for over 10% of total sales. For the year ended November 30, 2014, three customers accounted for 35% of revenue. As of November 30, 2016, three customers accounted for 64% of trade accounts receivable. As of November 30, 2015, seven customers accounted for 90% of accounts receivable. There was no accounts receivable as of November 30, 2014. Vulnerability Due to Operations in the PRC The Company’s operations may be adversely affected by significant political, economic and social uncertainties in the PRC. Although the PRC government has been pursuing economic reform policies for more than twenty years, no assurance can be given that the PRC government will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political disruption or unforeseen circumstances affecting the PRC’s political, economic and social conditions. There is also no guarantee that the PRC government’s pursuit of economic reforms will be consistent or effective. The economy in the PRC has recently started to narrow.

Issuance of Common Stock

Issuance of Common Stock	12 Months Ended
	Nov. 30, 2016
Issuance of Common Stock [Abstract]
ISSUANCE OF COMMON STOCK	10. ISSUANCE OF COMMON STOCK On January 18, 2016 the Company sold an aggregate of 12,000,000 shares of common stock to four individuals in a private offering. None of the purchasers were affiliated with the Company. The purchase price for the shares was three RMB (approximately US$0.4561) per share, or a total of 36 million RMB (approximately US$5,473,200). The purchase price was paid by the investors to Guangdong Gewang, which at that time was managed by the Company’s wholly-owned subsidiary and accounted for as a variable interest entity. On May 16, 2016 the Company sold an aggregate of 17,500,000 shares of common stock to two entities in a private offering. Neither of the purchasers were affiliated with the Company. The purchase price for the shares was US$0.25 per share, or a total of US$4,375,000. The purchase price was paid by the investors to Guangdong Gewang, which at that time was managed by a wholly-owned subsidiary of the Company and accounted for as a variable interest entity.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Nov. 30, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	11. COMMITMENTS AND CONTINGENCIES On December 30, 2015, the Company entered into a technology usage agreement with the Academy of Agricultural Sciences of Shandong Province (the "Academy") for the right of using a non-patented selenium-enrichment technology for its supplements manufacturing. The agreement commenced on December 30, 2015 and expires on December 29, 2020. Annual fee of RMB 600,000, approximately $87,000, is required to be paid in advance by the agreement before December 30 each year. As of September 1, 2016, the Company entered into a long-term agreement with the Academy. This agreement entitles the Company to the exclusive right of first refusal to use the research related to advanced selenium-enrichment techniques and technology that the Academy develops. The agreement calls for annual payments of approximately $2,324,000 (RMB 4,000,000) to be paid on a quarterly basis. For the use of the techniques and/or technology developed, there will be additional charges to be negotiated. On July 1, 2016, the Company entered into three year agreements with four of its directors for a total of approximately $15,000 (RMB 110,000) per month. On April 8, 2016, Guangdong Gewang entered into a Performance Salary Assessment Agreement with the Company’s Chief Executive Officer (“CEO”). The agreement states that the CEO would receive additional monthly compensation of RMB 50,000 (approximately $7,000), only when the monthly net income of Guangdong Gewang exceeds RMB 2,500,000 (approximately $363,000). The agreement commenced on April 8, 2016 and expires on April 7, 2017.

Parent Company Only Condensed F

Parent Company Only Condensed Financial Information	12 Months Ended
	Nov. 30, 2016
Parent Company Only Condensed Financial Information [Abstract]
PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION	12. PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION The following is the condensed financial information of China Gewang Biotechnology, Inc., the US parent, consisting of balance sheets as of November 30, 2016 and 2015, and statements of income and cash flows for the years ended November 30, 2016, 2015 and 2014. Condensed Balance Sheets ASSETS November 30, 2016 November 30, 2015 Other receivable from Guangdong Gewang $ 14,848,200 $ 5,000,000 Investments in subsidiaries and VIE 16,520,171 3,977,483 TOTAL ASSETS $ 31,368,371 $ 8,977,483 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accrued expenses $ 33,375 $ 33,375 Loans from third party 220,396 - Loan from stockholder 236,216 156,866 Total current liabilities 489,987 190,241 Stockholders’ equity: Common stock, $0.001 par value, 100,000,000 and 75,000,000 shares authorized, 75,000,000 and 45,500,000 shares issued and outstanding as of November 30, 2016, 2015 and 2014, respectively 75,000 45,500 Additional paid-in capital 16,980,102 6,525,743 Retained earnings 14,771,252 2,270,416 Statutory reserve fund 759,094 281,766 Other comprehensive (loss) income (1,707,064 ) (252,022 ) Total stockholder’s equity 30,878,384 8,787,242 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 31,368,371 $ 8,977,483 Condensed Statements of Income Year Ended November 30, 2016 2015 2014 Revenues: Share of earnings from investments in subsidiaries and VIE $ 13,358,543 $ 1,310,747 $ 724,555 Operating expenses: General and administrative 188,852 183,824 6,417 Net income $ 13,169,691 $ 1,126,923 $ 718,138 Condensed Statements of Cash Flows Year Ended November 30, 2016 2015 2014 Cash flows from operating activities: Net income $ 13,169,691 $ 1,126,923 $ 718,138 Adjustments to reconcile net income to net cash provided by (used in) operating activities Share of earnings from investment in subsidiaries and VIE (13,358,543 ) (1,310,747 ) (724,555 ) Increase in accrued expenses and other liabilities 188,852 183,824 6,417 Net cash provided by (used in) operating activities - - - Net change in cash - - - Cash, beginning of year - - - Cash, end of year $ - $ - $ - Noncash financing activities: Payment of accrued expenses and other payables by shareholder $ 298,938 $ 159,689 $ 6,417 Basis of Presentation The Company records its investment in its subsidiaries and VIE under the equity method of accounting. Such investments are presented as “Investments in subsidiaries and VIE” on the condensed balance sheets and the subsidiaries and VIE profits are presented as “Share of earnings from investments in subsidiaries and VIE” on the condensed statements of income. Certain information and footnote disclosures normally included in financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. The parent only financial information has been derived from the Company’s consolidated financial statements and should be read in conjunction with the Company’s consolidated financial statements. There were no cash transactions in the US parent company during the years ended November 30, 2016, 2015 and 2014. Restricted Net Assets Under the PRC laws and regulations, the Company’s PRC subsidiaries and VIE are restricted in their ability to transfer certain of their net assets to the Company in the form of dividend payments, loans or advances. The restricted net assets of the Company’s PRC subsidiaries and the VIE were approximately $31,368,000 and $8,977,000 as of November 30, 2016 and 2015, respectively. The Company’s operations and revenues are conducted and generated in the PRC, and all of the Company’s revenues being earned and currency received are denominated in RMB. RMB is subject to the foreign exchange control regulations in China, and, as a result, the Company may be unable to distribute any dividends outside of China due to the PRC foreign exchange control regulations that restrict the Company’s ability to convert RMB into US Dollars. Schedule I of Article 5-04 of Regulation S-X requires the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of the above test, restricted net assets of consolidated subsidiaries shall mean that amount of the Company’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by its subsidiaries in the form of loans, advances or cash dividends without the consent of a third party. The condensed parent company only financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X as the restricted net assets of the Company’s PRC subsidiaries exceed 25% of the consolidated net assets of the Company.

Subsequent Events

Subsequent Events	12 Months Ended
	Nov. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company’s management has performed subsequent events procedures through February 10, 2017, which is the date the consolidated financial statements were available to be issued. There were no subsequent events requiring adjustment to or disclosure in the consolidated financial statements

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Nov. 30, 2016
Summary of Significant Accounting Policies [Abstract]
Basis of accounting and presentation	Basis of accounting and presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include those of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company uses the equity method of accounting for its equity investments in Tianmei Australia. The investment was under common control and can be significantly influenced. Under the equity method, investments are carried at cost and increased or decreased by the Company’s pro-rata share of earnings or losses. The carrying costs of these investments is also increased or decreased to reflect additional contributions or withdrawals of capital. Any difference in the book equity and the Company’s pro-rata share of the net assets of the investment will be reported as gain or loss at the liquidation of the investment. Losses in excess of the investments are recorded when the Company is committed to provide additional financial support. The Company uses the equity method for investment of 30% because the Company has the ability to exercise significant influence over these entities. All consolidated financial statements and notes to the consolidated financial statements are presented in United States dollars (“US Dollar” or “US$” or “$”).
Use of estimates	Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.
Foreign currency translations	Foreign currency translations Almost all of the Company assets are located in the PRC. The functional currency for the Company’s operations is the Renminbi (“RMB”). The Company uses the United States Dollar (“US Dollar” or “US$” or “$”) for financial reporting purposes. The financial statements of the Company have been translated into US Dollars in accordance with Financial Accounting Standards Board ("FASB”) Accounting Standards Update ("ASU") Section 830, “ Foreign Currency Matters All asset and liability accounts have been translated using the exchange rate in effect at the balance sheet date. Equity accounts have been translated at their historical exchange rates when the capital transactions occurred. Statements of income (loss) and comprehensive income (loss), changes in stockholders’ equity and cash flows have been translated using the average exchange rate for the periods presented. Adjustments resulting from the translation of the Company’s financial statements are recorded as other comprehensive income (loss). The exchange rates used to translate amounts in RMB into US Dollars for the purposes of preparing the financial statements are as follows: November 30, 2016 November 30, 2015 November 30, 2014 Balance sheet items, except for stockholders’ equity, as of year end 0.1452 0.1561 0.1631 Year Ended November 30, 2016 2015 2014 Amounts included in the statements of income and comprehensive income, changes in stockholders’ equity and cash flows for the year presented 0.1515 0.1610 0.1628 For the years ended November 30, 2016, 2015 and 2014, foreign currency translation adjustments of $(1,455,633), $(315,020), and $1,333, respectively, have been reported as other comprehensive income (loss). Other comprehensive income (loss) of the Company consists entirely of foreign currency translation adjustments. Although PRC government regulations now allow convertibility of the RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that the RMB could be converted into US Dollars at that rate or any other rate. The value of the RMB against the US Dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC’s political and economic conditions. Any significant revaluation of the RMB may materially affect the Company’s financial condition in terms of US Dollar reporting. In August 2015, the PRC devalued its currency by approximately 3.5%; in January 2016 the PRC devalued its currency by an additional 0.5%; from February 2016 to November 2016, the PRC devalued its currency by an additional 7%. Further devaluations of its currency could occur.
Revenue recognition	Revenue recognition Revenues are primarily derived from selling selenium supplements and selenium products to wholesale customers, contract distributors, and from our retail stores. The Company’s revenue recognition policies comply with FASB ASC 605 “ Revenue Recognition. Wholesale Revenue Wholesale revenue is recognized when title to the product is transferred to the distributors. Title is transferred upon receipt at the distributors’ locations, as determined by the specific sales terms. The Company pays distributors certain incentives for promoting and placing its products, which allows the Company to quickly expand its distribution network and sales volume. The costs associated with these incentives is deducted from gross revenue in the consolidated statements of income and comprehensive income Retail Revenue Company-operated retail store revenues are recognized when payment is tendered at the point of sale. Franchise Revenue In June 2016, the Company commenced franchising the use of the Company's trademark, name identification and other business resources. The franchisee is required to pay franchise fees and management fees to the Company. Franchise fees are recognized only when all material services or conditions relating to the sale have been substantially performed or satisfied by the Company. In September 2016, the Company terminated its two franchise agreements for marketing reasons. The Company returned the total franchise fees to the franchisees and kept the management fees of $35,290 as per the termination agreements. The Company’s net revenues for the years ended November 30, 2016, 2015 and 2014 were comprised as follows: 2016 2015 2014 Wholesale gross revenue-selenium supplements $ 8,600,092 $ 2,945,440 $ 1,930,057 Wholesale gross revenue-selenium products 36,306,396 - - Less: promotion fees-selenium products, (3,745,883 ) - - Wholesale revenues, net 41,160,605 2,945,440 1,930,057 Retail revenue-selenium supplements 2,946,182 - - Retail revenues-selenium products 1,377,922 1,238,815 437,959 Management fee revenues 35,290 - - $ 45,519,999 $ 4,184,255 $ 2,368,016
Shipping costs	Shipping costs Shipping costs incurred by the Company are recorded as selling expenses. Shipping costs for the years ended November 30, 2016, 2015 and 2014 were $96,969, $44,326 and $27,545, respectively.
Advertising costs	Advertising costs Advertising costs are charged to operations when incurred. For the years ended November 30, 2016, 2015 and 2014, advertising expenses were $619,447, $82,110 and $70,013, respectively.
Cash and cash equivalents	Cash and cash equivalents The Company considers all demand and time deposits and all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Accounts receivable	Accounts receivable Accounts receivable are recorded at the contract amount after deduction of trade discounts and, allowances, if any, and do not bear interest. The allowance for doubtful accounts, when necessary, is the Company’s best estimate of the amount of probable credit losses from accounts receivable. The Company determines the allowance based on historical write-off experience, the level of past-due accounts based on the contractual terms of the receivable, the relationship with the customer and current economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. As of November 30, 2016, 2015 and 2014, accounts receivable were $11,205,011, $267,868 and $0, respectively. The increase is primarily due to the recent sales with new wholesale distributors which has been subsequently fully collected. Therefore, the Company determined that an allowance for doubtful accounts was not necessary. Historically, the Company did not have any uncollectable accounts receivable.
Inventory	Inventory Inventory, comprised principally of boxed selenium capsules, selenium-glossy ganoderma capsules and selenium powder, is valued at the lower of cost or market. The value of inventory is determined using the first-in, first-out method. The Company periodically estimates an inventory allowance for estimated unmarketable inventories when necessary. Inventory amounts are reported net of such allowances, if any. There were no allowances for inventory as of November 30, 2016, 2015 and 2014.
Fair value of financial instruments	Fair value of financial instruments FASB ASC 820, “Fair Value Measurement” Level 1 Inputs – Unadjusted quoted market prices for identical assets and liabilities in an active market that the Company has the ability to access. Level 2 Inputs – Inputs other than the quoted prices in active markets that are observable either directly or indirectly. Level 3 Inputs – Inputs based on valuation techniques that are both unobservable and significant to the overall fair value measurements. ASC 820 requires the use of observable market data, when available, in making fair value measurements. When inputs used to measure fair value fall within different levels of the hierarchy, the level within which the fair value measurement is categorized is based on the lowest level input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The Company did not identify any assets or liabilities that are required to be presented at fair value on a recurring basis. Carrying values of non-derivative financial instruments, including cash and cash equivalents, accounts receivable, inventory, prepaid expenses, equity investment, accounts payable, taxes payable, accrued liabilities and other payables, and loan from stockholder, approximated their fair values due to the short nature of these financial instruments. There were no changes in methods or assumptions during the periods presented.
Prepaid expenses	Prepaid expenses Prepaid expenses primarily consist of promotion expenses, rent, advertising expenses and licensing fees. Prepaid promotion expenses represent prepayments made to resellers for distributing products to retail stores. In March 2016, the Company entered into agreements with four distributors. In June, July and September 2016, the Company entered into agreements with another four distributors. Prepaid promotion expenses as of November 30, 2016, 2015 and 2014 were $4,275,602, $0 and $0, respectively. On January 5, 2011, the Company entered into a license agreement for the technology utilized for the manufacture of its products from an unrelated third party for five years from January 2011 to December 2015. On December 30, 2015, the Company renewed the license agreement for another five years to December 2020 for $90,872 (RMB 600,000) each year. The related prepaid licensing fees as of November 30, 2016, 2015 and 2014 were $7,259, $7,805 and $8,155, respectively. The license provides for renewal options. Since this agreement requires the advance payment of the annual licensing fee, there were no minimum payments remaining under this agreement as of November 30, 2016, 2015 and 2014. On September 30, 2016, the Company entered into a six-month agreement with an advertising company for $908,725 (RMB 6,000,000). As of November 30, 2016, the unamortized balance of $605,816 was included in prepaid expenses on the balance sheet.
Impairment of long-lived assets	Impairment of long-lived assets The Company applies FASB ASC 360, “ Property, Plant and Equipment
Statutory reserve fund	Statutory reserve fund Pursuant to corporate law of the PRC, the Company is required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory reserve fund until such reserve balance reaches 50% of the Company’s registered capital. The statutory reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or used to increase registered capital, provided that the remaining reserve balance after use is not less than 25% of registered capital. The statutory reserve fund was $759,094, $281,766, and $144,454 as of November 30, 2016, 2015 and 2014, respectively. As of November 30, 2016, the required statutory reserve fund has been fully funded.
Income taxes	Income taxes The Company accounts for income taxes in accordance with FASB ASC 740, “ Income Taxes ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, and accounting for interest and penalties associated with tax positions. As of November 30, 2016, 2015 and 2014, the Company does not have a liability for any unrecognized tax benefits. The Company’s tax filings are subject to examination by the tax authorities. The tax years of 2103, 2014 and 2015 remain open to examination by tax authorities in the PRC. The income tax laws of various jurisdictions in which the Company and its subsidiaries operate are summarized as follows: United States The Company is subject to United States tax at graduated rates from 15% to 35%. No provisions for income tax in the United States have been made as the Company had no U.S. taxable income for the years ended November 30, 2016, 2015 and 2014. British Virgin Islands BVI”) Biotechnology International is incorporated in the BVI and is governed by the income tax laws of the BVI. According to current BVI income tax law, the applicable income tax rate for the Company is 0%. Hong Kong Hong Kong Gewang is incorporated in Hong Kong. Pursuant to the income tax laws of Hong Kong, the Company is not subject to tax on non-Hong Kong source income. The People's Republic of China (“PRC”) Gewang Selenium and Guangdong Gewang are subject to an Enterprise Income Tax at 25% and file their own tax returns.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Nov. 30, 2016
Summary of Significant Accounting Policies [Abstract]
Schedule of exchange rates of balance sheet items	November 30, 2016 November 30, 2015 November 30, 2014 Balance sheet items, except for stockholders’ equity, as of year end 0.1452 0.1561 0.1631
Schedule of statements of income and comprehensive income, changes in stockholders' equity and cash flows	Year Ended November 30, 2016 2015 2014 Amounts included in the statements of income and comprehensive income, changes in stockholders’ equity and cash flows for the year presented 0.1515 0.1610 0.1628
Schedule of net revenues	2016 2015 2014 Wholesale gross revenue-selenium supplements $ 8,600,092 $ 2,945,440 $ 1,930,057 Wholesale gross revenue-selenium products 36,306,396 - - Less: promotion fees-selenium products, (3,745,883 ) - - Wholesale revenues, net 41,160,605 2,945,440 1,930,057 Retail revenue-selenium supplements 2,946,182 - - Retail revenues-selenium products 1,377,922 1,238,815 437,959 Management fee revenues 35,290 - - $ 45,519,999 $ 4,184,255 $ 2,368,016

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Nov. 30, 2016
Related Party Transactions [Abstract]
Schedule of changes in equity investment	November 30, 2016 November 30, 2015 November 30, 2014 Initial investment $ 1,466,652 $ - $ - Pro rata share of net income 4,536,760 - - Investment, end of year $ 6,003,412 $ - $ -
Summary of balance sheet of investee	Current assets $ 41,948,599 Noncurrent assets $ 1,321,713 Current liabilities $ 14,760,307 Noncurrent liabilities $ - Equity $ 28,510,005
Schedule of results of operations of the investee	Revenue $ 41,285,348 Cost of revenue (15,168,370 ) Expenses (10,994,445 ) Net income $ 15,122,533

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Nov. 30, 2016
Fixed Assets [Abstract]
Schedule of fixed assets	2016 2015 Electronic equipment $ 125,850 $ 68,733 Motor vehicles 121,151 69,714 Office equipment 12,031 12,936 259,032 151,383 Less: accumulated depreciation (130,265 ) (85,523 ) Fixed assets - net $ 128,767 $ 65,860

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Nov. 30, 2016
Income Taxes [Abstract]
Schedule of provision for income taxes	2016 2015 2014 Current $ 3,075,733 $ 457,922 $ 264,553 Deferred - - - $ 3,075,733 $ 457,922 $ 264,553

Parent Company Only Condensed25

Parent Company Only Condensed Financial Information (Tables)	12 Months Ended
	Nov. 30, 2016
Parent Company Only Condensed Financial Information [Abstract]
Summary of Condensed Balance Sheet	ASSETS November 30, 2016 November 30, 2015 Other receivable from Guangdong Gewang $ 14,848,200 $ 5,000,000 Investments in subsidiaries and VIE 16,520,171 3,977,483 TOTAL ASSETS $ 31,368,371 $ 8,977,483 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accrued expenses $ 33,375 $ 33,375 Loans from third party 220,396 - Loan from stockholder 236,216 156,866 Total current liabilities 489,987 190,241 Stockholders’ equity: Common stock, $0.001 par value, 100,000,000 and 75,000,000 shares authorized, 75,000,000 and 45,500,000 shares issued and outstanding as of November 30, 2016, 2015 and 2014, respectively 75,000 45,500 Additional paid-in capital 16,980,102 6,525,743 Retained earnings 14,771,252 2,270,416 Statutory reserve fund 759,094 281,766 Other comprehensive (loss) income (1,707,064 ) (252,022 ) Total stockholder’s equity 30,878,384 8,787,242 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 31,368,371 $ 8,977,483
Summary of Condensed Statements of Income	Year Ended November 30, 2016 2015 2014 Revenues: Share of earnings from investments in subsidiaries and VIE $ 13,358,543 $ 1,310,747 $ 724,555 Operating expenses: General and administrative 188,852 183,824 6,417 Net income $ 13,169,691 $ 1,126,923 $ 718,138
Summary of Condensed Cash Flow Statement	Year Ended November 30, 2016 2015 2014 Cash flows from operating activities: Net income $ 13,169,691 $ 1,126,923 $ 718,138 Adjustments to reconcile net income to net cash provided by (used in) operating activities Share of earnings from investment in subsidiaries and VIE (13,358,543 ) (1,310,747 ) (724,555 ) Increase in accrued expenses and other liabilities 188,852 183,824 6,417 Net cash provided by (used in) operating activities - - - Net change in cash - - - Cash, beginning of year - - - Cash, end of year $ - $ - $ - Noncash financing activities: Payment of accrued expenses and other payables by shareholder $ 298,938 $ 159,689 $ 6,417

Organization (Details)

Organization (Details)	Aug. 08, 2016USD ($)	Aug. 08, 2016CNY (¥)	Jul. 13, 2016USD ($)	Jul. 13, 2016CNY (¥)	Apr. 28, 2016USD ($)	Apr. 20, 2015shares	Nov. 30, 2016shares	Jul. 20, 2016shares	Nov. 30, 2015shares
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Equity of ownership percentage							30.00%
Common stock, shares authorized							100,000,000		75,000,000
Biotechnology International Holding Ltd. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Acquired percentage of Biotechnology international						100.00%
Shares of common stock						32,000,000
Equity of ownership percentage						90.14%
Articles of Incorporation [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock, shares authorized								100,000,000
Articles of Incorporation [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Common stock, shares authorized								75,000,000
Gewang Selenium [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Equity of ownership percentage	98.00%	98.00%	22.70%	22.70%
Payments to purchase price of equity	$ 1,500	¥ 9,800	$ 1,500	¥ 10,000
Yun Zeng [Member] | Haiping Wu [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Equity of ownership percentage	2.00%	2.00%
Sale of equity price	$ 30,400	¥ 200,000
Guangdong Tianmei [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Acquired percentage of Biotechnology international					30.00%
Payments to purchase price of equity | $					$ 1,000,000
Investment agreement payments, description					The $1,000,000 purchase price was paid in full on June 17, 2016.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details) - $ / shares	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Balance sheet items, except for stockholders' equity, as of year end	$ 0.1452	$ 0.1561	$ 0.1631

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details 1) - $ / shares	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Amounts included in the statements of income and comprehensive income, changes in stockholders' equity and cash flows for the year presented	$ 0.1515	$ 0.1610	$ 0.1628

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Details 2) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Summary of Significant Accounting Policies [Abstract]
Wholesale gross revenue-selenium supplements	$ 44,906,488	$ 2,945,440	$ 8,600,092
Wholesale gross revenue-selenium products			36,306,396
promotion fees-selenium products	(3,745,883)		(3,745,883)
Wholesale revenues, net	41,160,605	2,945,440	41,160,605
Retail revenue-selenium supplements	4,324,104	1,238,815	2,946,182
Retail revenues-selenium products			1,377,922
Management fee revenues	35,290		35,290
Revenues	$ 45,519,999	$ 4,184,255	$ 45,519,999

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Details Textual)	1 Months Ended				12 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	Dec. 30, 2015USD ($)	Dec. 30, 2015CNY (¥)	Nov. 30, 2016USD ($)	Nov. 30, 2015USD ($)	Nov. 30, 2014USD ($)
Summary of Significant Accounting Policies (Textual)
Percentage of equity					30.00%
Foreign currency translation adjustment					$ 1,455,633	$ 315,020	$ (1,333)
Currency transactions, Description					The PRC devalued its currency by approximately 3.5%; in January 2016 the PRC devalued its currency by an additional 0.5%; from February 2016 to November 2016, the PRC devalued its currency by an additional 7%.
Management fees					$ 35,290		35,290
Shipping costs					96,969	44,326	27,545
Advertising costs					619,447	82,110	70,013
Accounts receivable					11,205,011	267,868	0
License renewal cost per year			$ 90,872	¥ 600,000
Prepaid promotion expenses					4,275,602	0	0
Prepaid licensing fees					5,540,051	201,369
Statutory reserve fund					759,094	$ 281,766	$ 144,454
Advertising revenue	$ 908,725	¥ 6,000,000
Unamortized balance					$ 605,816
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Effective income tax rate					35.00%
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Effective income tax rate					15.00%
PRC [Member]
Summary of Significant Accounting Policies (Textual)
Effective income tax rate					25.00%
BVI [Member]
Summary of Significant Accounting Policies (Textual)
Effective income tax rate					0.00%

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Related Party Transactions [Abstract]
Initial investment
Pro rata share of net income	4,536,760
Investment, end of year	$ 6,003,412

Related Party Transactions (D32

Related Party Transactions (Details 1)	Nov. 30, 2016USD ($)
Related Party Transactions [Abstract]
Current assets	$ 41,948,599
Noncurrent assets	1,321,713
Current liabilities	14,760,307
Noncurrent liabilities
Equity	$ 28,510,005

Related Party Transactions (D33

Related Party Transactions (Details 2)	12 Months Ended
	Nov. 30, 2016USD ($)
Related Party Transactions [Abstract]
Revenue	$ 41,285,348
Cost of revenue	(15,168,370)
Expenses	(10,994,445)
Net income	$ 15,122,533

Related Party Transactions (D34

Related Party Transactions (Details Textual) - USD ($)	Jun. 17, 2016	Apr. 28, 2016	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014	Nov. 30, 2013
Related Party Transactions (Textual)
Loans from stockholder			$ 237,639
Equity Method Investments			6,003,412
Exceeded purchase price recorded to additional paid-in capital			$ 466,652
Equity of ownership percentage			30.00%
Promotions expenses			$ 626,147	0	0
Guangdong Tianmei [Member]
Related Party Transactions (Textual)
Trademark revenue			1,470	0	0
Future commitment			$ 1,500	$ 1,500	$ 1,500
License agreement, description			The Company entered into an agreement with Guangdong Tianmei on June 10, 2015 to license the use of the Company's trademark for 10 years.
Equity investment agreement [Member] | Biotechnology International Holding Ltd. [Member]
Related Party Transactions (Textual)
Investment agreement, description		At that time, 88% of the equity in Guangdong Tianmei was owned by two individuals who together directly or indirectly owned over 60% of the Company's outstanding shares.
Pay to acquire business		$ 1,000,000
Ownership interest, percentage		30.00%
Total payment of purchase price	$ 1,000,000
Investment agreement,maturity date	Jun. 20, 2016
Equity investment agreement [Member] | Guangdong Tianmei [Member]
Related Party Transactions (Textual)
Ownership interest, percentage			30.00%
Net worth of acquisition time			$ 4,888,840
Equity Method Investments			$ 1,466,652

Leases (Details)

Leases (Details)	Jun. 29, 2016	Aug. 31, 2016USD ($)	Aug. 31, 2016CNY (¥)	May 31, 2016USD ($)	Nov. 30, 2016USD ($)	Nov. 30, 2016CNY (¥)	Nov. 30, 2015USD ($)	Nov. 30, 2014USD ($)
Leases (Textual)
Prepaid lease payments					$ 221,123		$ 179,515
Rent expense					345,315		$ 181,125	$ 44,501
Warehouse and Office space [Member]
Leases (Textual)
Prepayment of total rent					$ 90,872	¥ 600,000
Lease expiration date	Jul. 1, 2017				Jul. 1, 2016	Jul. 1, 2016
Chancheng store [Member]
Leases (Textual)
Prepayment of total rent		$ 54,523	¥ 360,000		$ 41,801	¥ 276,000
Lease expiration date					Aug. 31, 2015	Aug. 31, 2015
Settlement fee				$ 4,576
Xiamen store [Member]
Leases (Textual)
Lease expiration date					Jun. 1, 2016	Jun. 1, 2016
Changsha store [Member]
Leases (Textual)
Prepayment of total rent					$ 63,611	¥ 420,000
Lease expiration date					Oct. 7, 2018	Oct. 7, 2018
Settlement fee				$ 0
Flagship store [Member]
Leases (Textual)
Prepayment of total rent					$ 145,396	¥ 960,000
Lease expiration date					May 31, 2017	May 31, 2017
Foshan store [Member]
Leases (Textual)
Prepayment of total rent					$ 63,611	¥ 420,000
Lease expiration date					May 31, 2017	May 31, 2017
Longyan store [Member]
Leases (Textual)
Prepayment of total rent					$ 63,611	¥ 420,000
Lease expiration date					May 31, 2017	May 31, 2017
Zhuzhou store [Member]
Leases (Textual)
Prepayment of total rent					$ 63,611	¥ 420,000
Lease expiration date					May 31, 2017	May 31, 2017

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	Nov. 30, 2016	Nov. 30, 2015
Property, Plant and Equipment [Line Items]
Fixed assets - gross	$ 259,032	$ 151,383
Less: accumulated depreciation	(130,265)	(85,523)
Fixed assets - net	128,767	65,860
Electronic equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets - gross	125,850	68,733
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Fixed assets - gross	121,151	69,714
Office equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets - gross	$ 12,031	$ 12,936

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Fixed Assets (Textual)
Depreciation expense	$ 52,919	$ 32,121	$ 25,962

Loans (Details)

Loans (Details) - USD ($)	Nov. 30, 2016	Nov. 30, 2015
Loans (Textual)
Loans from third party	$ 228,238
Loans from stockholder	$ 237,639

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Income Taxes [Abstract]
Current	$ 3,075,733	$ 457,922	$ 264,553
Deferred
Provision for income taxes	$ 3,075,733	$ 457,922	$ 264,553

Concentration of Credit and B40

Concentration of Credit and Business Risks (Details) - Customer	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Accounts Receivable [Member]
Concentration of Credit and Business Risks (Textual)
Percentage of credit concentration	64.00%	90.00%
Number of customers	3	7
Revenue [Member]
Concentration of Credit and Business Risks (Textual)
Percentage of credit concentration			35.00%
Number of customers			3
Sales [Member]
Concentration of Credit and Business Risks (Textual)
Percentage of credit concentration	48.00%	10.00%
Number of customers	3

Issuance of Common Stock (Detai

Issuance of Common Stock (Details) $ / shares in Units, ¥ in Millions	May 16, 2016USD ($)$ / sharesshares	Jan. 18, 2016USD ($)$ / sharesshares	Jan. 18, 2016CNY (¥)shares	Nov. 30, 2016USD ($)	Nov. 30, 2015USD ($)
Issuance of Common Stock (Textual)
Total common stock value | $				$ 9,848,200	$ 5,000,000
Common Stock [Member]
Issuance of Common Stock (Textual)
Common stock sale, shares | shares	17,500,000	12,000,000	12,000,000
Total common stock value	$ 4,375,000	$ 5,473,200	¥ 36
Purchase price per share | $ / shares	$ 0.25	$ 0.4561

Commitments and Contingencies (

Commitments and Contingencies (Details)	Sep. 01, 2016USD ($)	Sep. 01, 2016CNY (¥)	Apr. 08, 2016USD ($)	Apr. 08, 2016CNY (¥)	Dec. 30, 2015USD ($)	Dec. 30, 2015CNY (¥)	Jul. 01, 2016USD ($)Directors	Jul. 01, 2016CNY (¥)Directors	Apr. 08, 2016CNY (¥)
Commitments and Contingencies (Textual)
Annual fee for technology usage agreement					$ 87,000	¥ 600,000
Technology usage agreement commenced date					Dec. 30, 2015	Dec. 30, 2015
Technology usage agreement expires					Dec. 29, 2020	Dec. 29, 2020
Annual payments for long-term agreement	$ 2,324,000	¥ 4,000,000
Directors [Member] | Three Year Agreements [Member]
Commitments and Contingencies (Textual)
Due to all related parties							$ 15,000	¥ 110,000
Number of directors							4	4
Chief Executive Officer [Member] | Conditional Compensation Agreement [Member]
Commitments and Contingencies (Textual)
Due to all related parties			$ 7,000						¥ 50,000
Monthly net income			$ 363,000	¥ 2,500,000
Compensation agreement commenced date			Apr. 8, 2016	Apr. 8, 2016
Compensation agreement expires date			Apr. 7, 2017	Apr. 7, 2017

Parent Company Only Condensed43

Parent Company Only Condensed Financial Information (Details) - USD ($)	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
ASSETS
TOTAL ASSETS	$ 36,203,497	$ 9,360,909
Current liabilities:
Loans from third party	228,238
Loan from stockholder	237,639
Total current liabilities	4,815,511	405,345
Stockholders' equity:
Common stock, $0.001 par value, 100,000,000 and 75,000,000 shares authorized, 75,000,000 and 45,500,000 shares issued and outstanding as of November 30, 2016, 2015 and 2014, respectively	75,000	45,500
Additional paid-in capital	16,980,102	6,525,743
Retained earnings	15,026,053	2,270,416
Statutory reserve fund	759,094	281,766	$ 144,454
Other comprehensive (loss) income	(1,707,064)	(252,022)
Total stockholder's equity	31,133,185	8,871,403
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	36,203,497	9,360,909
Parent Company [Member]
ASSETS
Other receivable from Guangdong Gewang	14,848,200	5,000,000
Investments in subsidiaries and VIE	16,520,171	3,977,483
TOTAL ASSETS	31,368,371	8,977,483
Current liabilities:
Accrued expenses	33,375	33,375
Loans from third party	220,396
Loan from stockholder	236,216	156,866
Total current liabilities	489,987	190,241
Stockholders' equity:
Common stock, $0.001 par value, 100,000,000 and 75,000,000 shares authorized, 75,000,000 and 45,500,000 shares issued and outstanding as of November 30, 2016, 2015 and 2014, respectively	75,000	45,500
Additional paid-in capital	16,980,102	6,525,743
Retained earnings	14,771,252	2,270,416
Statutory reserve fund	759,094	281,766
Other comprehensive (loss) income	(1,707,064)	(252,022)
Total stockholder's equity	30,878,384	8,787,242
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 31,368,371	$ 8,977,483

Parent Company Only Condensed44

Parent Company Only Condensed Financial Information (Details 1) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Operating expenses:
General and administrative	$ 1,005,385	$ 528,627	$ 150,154
Net income	13,574,670	1,188,713	784,152
Parent Company [Member]
Revenues:
Share of earnings from investments in subsidiaries and VIE	13,358,543	1,310,747	724,555
Operating expenses:
General and administrative	188,852	183,824	6,417
Net income	$ 13,169,691	$ 1,126,923	$ 718,138

Parent Company Only Condensed45

Parent Company Only Condensed Financial Information (Details 2) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015	Nov. 30, 2014
Cash flows from operating activities:
Net income	$ 13,574,670	$ 1,188,713	$ 784,152
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Increase in accrued expenses and other liabilities	207,689	330,936	9,410
Net cash provided by (used in) operating activities	(2,835,968)	1,037,620	728,904
Net change in cash	4,439,306	5,656,222	723,594
Cash, beginning	8,669,034	3,012,812	2,289,218
Cash, end	13,108,340	8,669,034	3,012,812
Noncash financing activities:
Payment of accrued expenses and other payables by shareholder	298,938	159,689	6,417
Parent Company [Member]
Cash flows from operating activities:
Net income	13,169,691	1,126,923	718,138
Adjustments to reconcile net income to net cash provided by (used in) operating activities
Share of earnings from investment in subsidiaries and VIE	(13,358,543)	(1,310,747)	(724,555)
Increase in accrued expenses and other liabilities	188,852	183,824	6,417
Net cash provided by (used in) operating activities
Net change in cash
Cash, beginning
Cash, end
Noncash financing activities:
Payment of accrued expenses and other payables by shareholder	$ 298,938	$ 159,689	$ 6,417

Parent Company Only Condensed46

Parent Company Only Condensed Financial Information (Details Textual) - USD ($)	12 Months Ended
	Nov. 30, 2016	Nov. 30, 2015
Parent Company Only Condensed Financial Information (Textual)
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	75,000,000
Common stock, shares issued	75,000,000	45,500,000
Common stock, shares outstanding	75,000,000	45,500,000
Restricted Net Assets [Member]
Parent Company Only Condensed Financial Information (Textual)
Variable interest entity amount	$ 31,368,000	$ 8,977,000
Restricted net assets, Percentage	25.00%
Parent Company [Member]
Parent Company Only Condensed Financial Information (Textual)
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	75,000,000
Common stock, shares issued	75,000,000	45,500,000
Common stock, shares outstanding	75,000,000	45,500,000